Maviret coated granules is indicated for the treatment of acute and chronic hepatitis C virus (HCV) infection in children 3 years and older. Maviret is indicated for the treatment of acute and chronic hepatitis C virus (HCV) infection in adults and children aged 3 years and older.
MAVYRET — ABBVIE, approved 2025-06-10 (NDA215110).
9,212 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.